Home     About Us     Team     Products     News     Contact     FAQ     Account

Drugs & Biologicals

Bosutinib (trade name Bosulif) received US FDA and EU European Medicines Agency approval on September 4, 2012 and 27 March 2013 respectively for the treatment of adult patients with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance, or intolerance to prior therapy... Wikipedia

 

 

Manufacturer's Website: Bosulif                                                                                                                  Average retail cost: $5,188/month

 

Search Terms: Bosulif, bosutinib, Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML)

Copyright 2006-2022 Automated Clinical Guidelines, LLC. All rights reserved.